The invention relates to a method for embedding a load based on gel high hydrostatic pressure liquefaction. Using the phenomenon that the physical gel is liquefied under high pressure, the vacuum-packaged high-methoxyl pectin gel is treated under a pressure of 400-600 MPa for 5-30 min, mixed with the load, and then subjected to a pressure of 400-600 MPa for homogenization treatment for 5 to 30 min. After pressure relief, the liquefied gel is poured into a mold for reshaping, followed by removal of free water and coating treatment. This method combines the advantages of high hydrostatic pressure technology in modification and sterilization. It has mild embedding conditions and wide sources of raw materials to prepare the carrier, which has excellent biocompatibility and biodegradability. It can be widely used for embedding microorganisms, enzymes, proteins and small molecular substances. The loaded gel prepared by the method has high microbial safety, can effectively maintain the activity of the load. The load distribution is uniform, and the load amount is much larger than the traditional adsorption load.

The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A method of improving kidney function in an adult patient with hepatorenal syndrome with rapid reduction in kidney function may include determining the patient’s acute-on-chronic liver failure (ACLF) grade and baseline serum creatinine level; obtaining a baseline oxygenation saturation (SpO.sub.2) of the patient; administering a dose of terlipressin acetate to the patient by intravenous (IV) injection; and monitoring the patient’s oxygenation saturation with pulse oximetry.

The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A method of improving kidney function in an adult patient with hepatorenal syndrome with rapid reduction in kidney function may include determining the patient’s acute-on-chronic liver failure (ACLF) grade and baseline serum creatinine level; obtaining a baseline oxygenation saturation (SpO.sub.2) of the patient; administering a dose of terlipressin acetate to the patient by intravenous (IV) injection; and monitoring the patient’s oxygenation saturation with pulse oximetry.

Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 μM to 1 mM; and (ii) a thrombin component containing thrombin. Further disclosed is an anti-adhesion kit comprised of: (i) a fibrinogen solution component containing fibrinogen at a concentration of 8% to 25% of total protein by weight, and optionally free calcium ions at a concentration ranging from 0.1 μM to 1 mM; wherein a total protein concentration ranges from about 80 to 120 mg/ml; and (ii) a thrombin component containing thrombin. Methods of using the kits e.g., to provide anti-adhesion curable compositions are also disclosed.

Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 μM to 1 mM; and (ii) a thrombin component containing thrombin. Further disclosed is an anti-adhesion kit comprised of: (i) a fibrinogen solution component containing fibrinogen at a concentration of 8% to 25% of total protein by weight, and optionally free calcium ions at a concentration ranging from 0.1 μM to 1 mM; wherein a total protein concentration ranges from about 80 to 120 mg/ml; and (ii) a thrombin component containing thrombin. Methods of using the kits e.g., to provide anti-adhesion curable compositions are also disclosed.

Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 μM to 1 mM; and (ii) a thrombin component containing thrombin. Further disclosed is an anti-adhesion kit comprised of: (i) a fibrinogen solution component containing fibrinogen at a concentration of 8% to 25% of total protein by weight, and optionally free calcium ions at a concentration ranging from 0.1 μM to 1 mM; wherein a total protein concentration ranges from about 80 to 120 mg/ml; and (ii) a thrombin component containing thrombin. Methods of using the kits e.g., to provide anti-adhesion curable compositions are also disclosed.

The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.

The invention provides hydrogel, wherein the hydrogel has a supramolecular cross-linked network obtainable or obtained from the complexation of an aqueous composition including a host, such as cucurbituril, and one or more polymers having suitable guest functionality. One or more polymers in the aqueous composition may have a molecular weight of 50 kDa or more, such as 200 kDa or more. The hydrogel may hold a component, such as a therapeutic compound or a biological molecule. The hydrogels are suitable for use in medicine.

Compounds are described and characterized that bind guanine quadruplexes of DNA or RNA. Binding data and inhibition of growth data of five cancer cell lines are presented.

Provided herein are methods for treating coronavirus diseases. In one embodiment, the method comprises administering to a coronavirus disease patient a therapeutic amount of decidua stromal cells. In one embodiment, the method comprises administering to the subject a therapeutic amount of decidua stromal cells (DSCs). In some embodiments, the coronavirus disease is SARS, MERS or COVID-19. The method of the disclosure can be used to treat a subject who has acute respiratory distress syndrome (ARDS), acute lung injury (ALI), or both.